3360:HKEXFar East Horizon Limited Analysis

Ship Healthcare is trading just above its 20‑day SMA (≈2083) but remains well under the 50‑day (≈2223) and 200‑day (≈2422) averages, confirming a short‑term bearish bias despite a modest bullish MACD histogram and rising volume. The RSI of 44.5 suggests the stock is not yet oversold, while the current price of 2,094 sits near the identified resistance of 2,141.5 and above the support level of 1,938, implying limited downside cushion. On the fundamentals side, a trailing P/E of 14.5 versus an industry average of 24.1 points to a clear valuation discount, and the forward P/E of 11.4 signals further upside potential. The DCF‑derived fair value of roughly 4,000 JPY translates to an upside of over 30% from today’s price, reinforced by analyst median targets around 2,500 JPY. Cash holdings (≈80.6 bn JPY) comfortably exceed debt (≈30.4 bn JPY), yielding a modest debt‑to‑equity of ~20% and a healthy free cash flow stream that supports the 3.1% dividend yield. With a payout ratio near 42%, the dividend appears sustainable. Volatility remains high at ~40% over 30 days, but the stock’s beta is low, indicating limited market‑wide systematic risk. Overall, the combination of a solid balance sheet, attractive yield, and significant valuation gap makes the stock a compelling candidate for upside, provided investors can tolerate the near‑term price weakness.